6 completed, 4 recruiting, 2 active not recruiting, 2 terminated. 17 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 6, Recruiting 4, Active not recruiting 2, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 7 | Recruiting 3, Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
Follow Non-muscle Invasive Bladder Cancer: new trials by email Literature Review of Non-muscle Invasive Bladder Cancer trials Research Report on Non-muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer PF-08052667, Sasanlimab, BCG - Non-muscle Invasive Bladder Cancer | Phase 1 | Recruiting | Pfizer | 294 | 2025-11-06 | 2026-10-13 |
| A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC) Eciskafusp Alfa, BCG Medac Strain - Non-muscle Invasive Bladder Cancer | Phase 1 | Withdrawn | Hoffmann-La Roche | 2025-06-15 | 2025-06-16 | |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) Sacituzumab tirumotecan, Rescue medication, Supportive care measures - Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 32 | 2024-12-20 | 2026-10-15 |
| A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer Recombinant oncolytic adenovirus injection solution of VT-101 - Non-muscle Invasive Bladder Cancer | Phase 1 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 16 | 2024-09-18 | 2024-10-09 |
| Study of CG0070 After Transurethral Resection in Patients With IR NMIBC CG0070 - Non-muscle Invasive Bladder Cancer | Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2024-03-01 | 2026-07-02 |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) TARA-002 - Non-muscle Invasive Bladder Cancer | Phase 1 | Completed | Protara Therapeutics | 10 | 2023-05-08 | 2025-01-27 |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) UGN-301, UGN-201, Gemcitabine - Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Completed | UroGen Pharma Ltd. | 51 | 2022-06-01 | 2026-01-14 |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) TARA-002 - Non-muscle Invasive Bladder Cancer | Phase 1 | Completed | Protara Therapeutics | 12 | 2022-03-10 | 2025-01-27 |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) Enfortumab vedotin - Urinary Bladder Neoplasms, Carcinoma in Situ | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 37 | 2021-12-07 | 2026-09-14 |
| Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11 - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 115 | 2021-11-08 | 2026-08-14 |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy) - Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 1 / Phase 2 | Recruiting | enGene, Inc. | 350 | 2021-04-22 | 2026-08-07 |
| A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer alpha1H, 7.4 mg/mL, placebo, alpha1H, 37 mg/mL - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Hamlet Pharma AB | 52 | 2018-05-21 | 2020-08-19 |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer TSD-001 - Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Completed | Lipac Oncology LLC | 15 | 2018-05-17 | 2025-06-27 |
| CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) CVA21, Mitomycin C - Non-muscle Invasive Bladder Cancer | Phase 1 | Completed | Viralytics | 16 | 2015-01-16 | 2022-07-27 |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation) - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Active not recruiting | ImmunityBio, Inc. | 369 | 2014-07-21 | 2026-03-31 |
| A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer ALT-801, Gemcitabine - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Terminated | Altor BioScience | 12 | 2012-03-30 | 2024-07-19 |
| Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer cis-UCA solution - Non-muscle Invasive Bladder Cancer | Phase 1 | Completed | BioCis Pharma Ltd | 12 | 2009-10-01 | 2012-11-12 |
Non-Muscle Invasive Bladder Neoplasms (17) · Urinary Bladder Neoplasms (12) · Carcinoma in Situ (5) · Carcinoma, Transitional Cell (3) · Neoplasms (3) · Recurrence (2) · Urinary Bladder Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
Carcinoma (17) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Male Urogenital Diseases (17) · Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Glandular and Epithelial (17) · Urogenital Diseases (17) · Urinary Bladder Diseases (16) · Urogenital Neoplasms (16) · Urologic Diseases (16) · Urologic Neoplasms (16) · Neoplasms (14) · Urinary Bladder Neoplasms (5) · Disease Attributes (2)
Gemcitabine (2) · ALT-801 (1) · ALT-803 (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Imiquimod (1) · Mitomycin (1) · Surface-Active Agents (1) · enfortumab vedotin (1)
Protara Therapeutics (2) · Altor BioScience (1) · Astellas Pharma Global Development, Inc. (1) · BioCis Pharma Ltd (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hamlet Pharma AB (1) · Hoffmann-La Roche (1) · ImmunityBio, Inc. (1) · Lipac Oncology LLC (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Pfizer (1) · The Affiliated Hospital of Xuzhou Medical University (1) · UroGen Pharma Ltd. (1) · Viralytics (1)
United States (12) · Spain (6) · United Kingdom (5) · France (4) · Canada (3) · Italy (3) · Australia (2) · Germany (2) · Netherlands (2) · South Korea (2) · China (1) · Czechia (1) · Finland (1) · India (1) · Israel (1)
Bernard Bochner, MD (1) · Bobby Reddy, MD (1) · Christine Tosone, Ms, RAC (1) · Hailong Li, M.D/Ph.D (1) · Hardev Pandha (1) · Juha Peltonen, MD (1) · Junnian Zheng, M.D/Ph.D (1) · Marek Babjuk, MD, Prof. (1) · Meng Lu, Ph.D (1) · Michael Oefelein, MD (1)
PMID 23088985, PMID 26014293, PMID 28712033, PMID 28755959, PMID 28886381, PMID 28981385, PMID 31273010, PMID 32615118, PMID 33924556, PMID 34103518, PMID 38553868, PMID 38953850, PMID 39035212, PMID 42008114, PMID 42337683
2009 (1), 2014 (1), 2016 (1), 2023 (1)